Merck & Co., Inc.

MRKLast close 144.30 USD · Oct 2, 2026

Machine signal

Active cluster sell — 5 distinct insiders, $30M, window ends Aug 13, 2026.

Insider trading at Merck & Co., Inc.

Transactions on record: 818; since Aug 1, 2003

Insider buys: 25; $7M

Insider sells: 69; $71.3M

Active insiders · 12 months: 8; last filing Oct 1, 2026

Figures computed from official regulatory filings — .

Company financials

Revenue (TTM): 66.6B

EBITDA: 28.9B

EPS (TTM): 1.26

Profit margin: 4.8%

Return on equity: 7.0%

Revenue growth (YoY): 5.1%

P/E ratio: 114.52

Forward P/E: 15.29

Price / sales: 5.35

EV / EBITDA: 10

Price / book: 8.71

Dividend yield: 2.3%

52-week range: 79.67–156

Analysttarget 155.76 USD (+8%) · consensus 4.22/5 · 19 buy · 8 hold · 0 sell

Ownershipinsiders 0.06% · institutions 83.04% · short 1.4% of float

In USD · as of Oct 5, 2026

Insiders on record at Merck & Co., Inc.

Show all 54 insiders on record

About the company

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Insider	Filed	Type	Qty	Price	Value · USD	Signals	Src	Details
Coe Mary Ellen	Oct 1, 2026	AwardD (derivative)	206.46	145.31 USD	$30K		SEC

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NYSE

Listing on recordSecurity status from the latest source received, not a guarantee of tradability.

Former names

Periods recorded in the consulted sources. These do not certify the legal dates of name changes.

Merck & Co. Inc.Nov 4, 2009 / Dec 9, 2014
SCHERING PLOUGH CORPDec 29, 1994 / Oct 29, 2009

Merck & Co., Inc.

Insider trading at Merck & Co., Inc.

Company financials

Insiders on record at Merck & Co., Inc.

Merck & Co., Inc.

Insider trading at Merck & Co., Inc.

Company financials

Insiders on record at Merck & Co., Inc.

Insider transaction history at Merck & Co., Inc.

About the company

Insider transaction history at Merck & Co., Inc.